Lyra Therapeutics Q1 2023 net loss $16.3M; ENLIGHTEN I Phase 3 on track for 1H 2024 data

Lyra Therapeutics, Inc.

2023-Q1 EPS reported -$0.44 revenue$410,000

Net loss of $16.3M for Q1 2023, compared to $11.9M in Q1 2022.
Cash, equivalents, and short-term investments $82.7M at March 31, 2023; cash runway into mid-Q2 2024.
ENLIGHTEN I Phase 3 trial (LYR-210, pre-surgical CRS) enrollment ongoing; data expected 1H 2024.
ENLIGHTEN II Phase 3 trial restarted enrollment in April 2023; completion expected H2 2024.
BEACON Phase 2 trial (LYR-220, post-surgical CRS) enrollment complete; data expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyra Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $16.3 million.

Period: the first quarter ended March 31, 2023
Net income: $16.3 million
Result: reported results

Exact text from the filing

Net loss for the first quarter 2023 was $16.3 million compared to $11.9 million for the same period in 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.